M&A

JATT II to merge with Talawar in $120M deal, backed by $225M PIPE

What's the deal? JATT II Acquisition CorpDealroom has a profile for this one. Try Dealroom → has agreed to merge with Talawar Tx, a biotechnology company, in a stock transaction valued at $120 million. On November 9, 2026, JATT filed a definitive proxy statement seeking shareholder approval, with Talawar becoming the surviving public company.

The terms: JATT shareholders will receive one share of Post-Closing Company Common Stock for each JATT Ordinary Share held. The exchange ratio divides $120 million by $10.00 per share, producing a pro forma fully-diluted count of 42.7 million shares under a no-redemption scenario.

The PIPE: The deal includes a $225 million private investment in public equity. Investors, including affiliates of Talawar's chief executive officer and Access BiotechnologyDealroom has a profile for this one. Try Dealroom →, committed to buy 22,500,000 shares at $10.00 each.

What's the endgame? Talawar is developing bispecific antibodies for immune and skin diseases. Its lead program, TALA-125, targets atopic dermatitis; the combined proceeds are intended to fund it through a Phase 2b readout in 2028.

Why now? Biotech reverse mergers have surged, with BioPharma DiveDealroom has a profile for this one. Try Dealroom → counting roughly two dozen announced in 2026 through early September — more than double the 10 recorded in all of 2025. Large PIPEs are increasingly central to funding these deals, as in Corxel's planned SPAC merger backed by about $300 million.

What could go wrong? Closing depends on shareholder approval and a Minimum Cash Condition, which permits up to 6 million redemptions by public shareholders. JATT will hold an extraordinary general meeting on December 2, 2026; the merger itself requires a 66-2/3% special resolution.

The signal: Talawar's $225 million PIPE is substantial against a backdrop of returning investor interest in biotech listings. But as the market context underscores, these deals remain highly dependent on committed cash and shareholder support — execution, not appetite, is the open question.

Read more: kalkinemedia.com

Image credit: Talawar Therapeutics

More top stories